A Study to Evaluate the Combination of Binimetinib and Palbociclib in Treating Patients with KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Overview

About this study

The purose of this study is to determine how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive colorectal cancer that has spread to other places in the body or cannot be removed by surgery. Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving binimetinib and palbociclib may work better compared to TAS-102 alone in treating patients with colorectal cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria: 

 

  • Age ≥ 18 years.
  • Histological confirmation of colorectal cancer that is metastatic and/or unresectable.
  • Documented mutation in KRAS or NRAS (codon 12, 13, 59, 61, 117, or 146) in tumor tissue from primary or metastatic site, tested by a CLIA-certified laboratory.
  • Measurable disease.
  • ECOG Performance Status (PS) of 0 or 1.
    • Note: Form is available on the ACCRU web site.
  • Previously treated with ≥ 2 prior regimens of systemic chemotherapy for metastatic or locally advanced, unresectable disease.
    • Note: Maintenance regimens, such as 5-fluorouracil or capecitabine, with or without bevacizumab, should not be counted as separate lines of treatment.
    • Note: For patients who experienced disease recurrence during or within 6 months of completion of adjuvant chemotherapy, only one regimen of systemic chemotherapy for metastatic disease is required.
  • The following laboratory values obtained ≤ 14 days prior to registration/randomization unless otherwise noted.
    • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L;
    • Platelet count ≥ 75 x 10^9/L without transfusions;
    • Hemoglobin (Hgb) ≥ 9 g/dL;
    • Total bilirubin ≤ 1.5 x upper limit of normal (ULN);
    • Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; ≤ 5.0 x ULN if known liver metastases;
    • Serum creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula below:
    • Cockcroft-Gault Equation:
      • Creatinine clearance for males =         (140 - age)(weight in kg)
                                                             (72)(serum creatinine in mg/dL)
      • Creatinine clearance for females = (140 - age)(weight in kg)(0.85)
                                                                (72)(serum creatinine in mg/dL)
  • Negative serum β-HCG pregnancy test done ≤ 7 days prior to registration/randomization for women of childbearing potential only.
  • Able to swallow capsules with no surgical or anatomic conditions that would preclude the patient from swallowing and absorbing oral medications.
  • Able and willing to provide informed written consent and able to comply with protocol requirements.
  • Able and willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
    • Note: During the Active Monitoring Phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up.
  • Willing to provide blood and tissue samples for mandatory correlative research purposes.
  • Patient is deemed by the Investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up).

Exclusion Criteria: 

  • Prior treatment with drug targeting BRAF, MEK, ERK, or CDK family.
    • Note: For the purpose of this protocol, prior treatment with regorafenib is allowed.
  • Prior treatment with trifluridine/tipiracil (TAS-102).
  • Pregnant or nursing (lactating women), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Women of child-bearing potential.
    • Note: defined as all women physiologically capable of becoming pregnant, unless they agree to use highly effective methods of contraception throughout the study and for 8 weeks after study drug discontinuation.
    • N: Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation ≥ 42 days prior to registration/randomization. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child bearing potential.
  • Sexually active males.
    • Note: unless they agree to use highly effective methods of contraception throughout the study and for 12 weeks after study drug discontinuation and should not father a child in this period.
  • Any symptomatic brain metastasis.
    • Note: Patients previously treated or untreated for this condition who are asymptomatic in the absence of corticosteroid and anti-epileptic therapy are allowed. Brain metastases must be stable for ≥ 4 weeks prior to registration/randomization, with imaging (e.g., magnetic resonance imaging [MRI] or computed tomography [CT]) demonstrating no current evidence of progressive brain metastases at registration/randomization.
  • Prior treatment ≤ 21 days prior to registration/randomization with any other chemotherapy, small molecule inhibitor (e.g. regorafenib), monoclonal antibody, immunotherapy, or radiotherapy.
    • Note: All toxicities from prior therapy must be ≤ Grade 1 (or ≤ Grade 2 for peripheral neuropathy or alopecia).
  • Impaired cardiovascular function or clinically significant cardiac diseases, including any of the following:
    • History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) <6 months prior to registration/randomization;
    • Symptomatic chronic heart failure (i.e. Grade 2 or higher), history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality <6 months prior to registration/randomization except atrial fibrillation and paroxysmal supraventricular tachycardia;
    • Left ventricular ejection fraction (LVEF) <50% as determined by a multigated acquisition (MUGA) scan or echocardiogram ≤ 28 days prior to registration/randomization.
  • Uncontrolled hypertension, defined as persistent elevation of systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100mmHg despite current therapy.
  • History of thromboembolic or cerebrovascular events ≤ 12 weeks prior registration/randomization. Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (i.e., massive or submassive)
  • deep vein thrombosis or pulmonary emboli.
    • Note: Patients with either deep vein thrombosis or pulmonary emboli that does not result in hemodynamic instability are allowed to enroll as long as they are on a stable dose of anticoagulants for at least 4 weeks.
    • Note: Patients with thromboembolic events related to indwelling catheters or other procedures may be enrolled.
  • Known history of acute or chronic pancreatitis ≤ 6 months prior to registration/randomization.
  • Known positive serology for HIV (human immunodeficiency virus), active hepatitis B, and/or active hepatitis C infection.
  • Patients who have neuromuscular disorders that are associated with elevated CPK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
  • History of chronic inflammatory bowel disease or Crohn’s disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to registration/randomization.
  • Impaired GI function or disease that may significantly alter the absorption of binimetinib or palbociclib (e.g., ulcerative disease, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption) in the opinion of the investigator.
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors to RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).
  • Leptomeningeal disease.
  • Known hypersensitivity to the components of study drugs or its analogs.
  • Known medical, psychiatric, substance abuse, or cognitive disorder that may compromise the patient's ability to understand the patient information, give informed consent, comply with the study protocol or complete the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator.
  • Patients who have undergone major surgery ≤ 21 days prior to registration/randomization or who have not recovered from side effects of such procedures.
  • Any other co-morbid, systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Previous or concurrent malignancy ≤ 3 years prior to registration/randomization with the following exceptions:
    • adequately treated basal cell or squamous cell carcinoma of the skin;
    • superficial bladder cancer;
    • prostate intraepithelial neoplasm;
    • in situ carcinoma of the cervix;
    • other solid tumors treated curatively without evidence of recurrence for ≥ 3 years prior to registration/randomization.
    • Note: If there is a history or prior malignancy, must not be receiving other specific anti-cancer treatment such as anti-estrogen, anti-androgen, or other tyrosine kinase inhibitor therapy.
    • Note: Re-registration must occur ≤ 28 days from Part 2 TAS-102 disease progression (PD).
  • Upon confirmation of progression for patients in Arm B (TAS-102) of randomized portion of the trial, patients may elect to cross-over to treatment with binimetinib + palbociclib as long as the following criteria are met:

Crossover Inclusion Criteria:

  • Age ≥ 18 years.
  • Histological confirmation of colorectal cancer that is metastatic and/or unresectable.
    • Documented mutation in KRAS or NRAS (codon 12, 13, 59, 61, 117, or 146) in tumor tissue from primary or metastatic site, tested by a CLIA certified laboratory.
  • Measurable disease as defined in Section 11.0.
  • ECOG Performance Status (PS) of 0 or 1.
  • Previously treated with ≥ 2 prior regimens of systemic chemotherapy for metastatic or locally advanced, unresectable disease.
    • Note: Maintenance regimens, such as 5-fluorouracil or capecitabine, with or without bevacizumab, should not be counted as separate lines of treatment.
    • Note: For patients who experienced disease recurrence during or within 6 months of completion of adjuvant chemotherapy, only one regimen of systemic chemotherapy for metastatic disease is required.
  • The following laboratory values obtained ≤ 28 days of Re-registration unless otherwise noted:
    • Absolute neutrophil count (ANC ≥ 1.5 x 10^9/L)
    • Platelet count ≥ 75 x 10^9/L without transfusion
    • Hemoglobin (Hgb) ≥9 g/dL
    • Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
    • Aspartate transaminase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; ≤ 5.0 x ULN if known liver metastases
    • Serum creatinine ≤ 1.5 mg/dL OR calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault formula below:
      • Cockcroft-Gault Equation:
      • Creatinine clearance for males = (140 - age)(weight in kg)
                                                             (72)(serum creatinine in mg/dL)
      • Creatinine clearance for females = (140 - age)(weight in kg)(0.85)
                                                                (72)(serum creatinine in mg/dL)
  • Negative serum β-HCG pregnancy test done ≤ 7 days prior to Reregistration for women of childbearing potential only.
  • Able to swallow capsules with no surgical or anatomic conditions that would preclude the patient from swallowing and absorbing oral medications.
  • Able and willing to provide informed written consent and able to comply with protocol requirements.
  • Able and willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
    • Note: During the Active Monitoring phase of a study (i.e., active treatment and observation), participants must be willing to return to the consenting institution for follow-up.
  • Willing to provide blood samples for mandatory correlative research purposes.
  • Patient is deemed by the Investigator to have the initiative and means to be compliant with the protocol (treatment and follow-up).

Crossover Exclusion Criteria:

  • Prior treatment with drug targeting BRAF, MEK, ERK, or CDK family.
    • Note: For the purpose of this protocol, prior treatment with regorafenib is allowed.
  • Pregnant or nursing (lactating women), where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Women of child-bearing potential.
    • Note: Defined as all women physiologically capable of becoming pregnant, unless they agree to use highly effective methods of contraception throughout the study and for 8 weeks after study drug discontinuation.
    • Note: Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation ≥ 42 days of Re-registration. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child bearing potential.
  • Sexually active males.
    • Note: unless they agree to use highly effective methods of contraception throughout the study and for 12 weeks after study drug discontinuation and should not father a child in this period. Study Contraception Guidelines for acceptable forms of highly effective methods of contraception.
  • Any symptomatic brain metastasis.
    • Note: Patients previously treated or untreated for this condition who are asymptomatic in the absence of corticosteroid and anti-epileptic therapy are allowed. Brain metastases must be stable for ≥ 4 weeks, with imaging (e.g., magnetic resonance imaging [MRI] or computed tomography [CT]) demonstrating no current evidence of progressive brain metastases at Re-registration.
  • Impaired cardiovascular function or clinically significant cardiac diseases, including any of the following:
    • History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) < 6 months prior to Reregistration
    • Symptomatic chronic heart failure (i.e., Grade 2 or higher), history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality < 6 months prior to Re-registration except atrial fibrillation and paroxysmal supraventricular tachycardia
    • Left ventricular ejection fraction (LVEF) < 50% as determined by a multigated acquisition (MUGA) scan or echocardiogram.
  • Uncontrolled hypertension, defined as persistent elevation of systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg despite current therapy.
  • History of thromboembolic or cerebrovascular events ≤ 12 weeks prior re-registration. Examples include transient ischemic attacks, cerebrovascular accidents, hemodynamically significant (i.e. massive or sub-massive) deep vein thrombosis or pulmonary emboli.
    • Note: Patients with either deep vein thrombosis or pulmonary emboli that does not result in hemodynamic instability are allowed to enroll as long as they are on a stable dose of anticoagulants for at least 4 weeks.
    • Note: Patients with thromboembolic events related to indwelling catheters or other procedures may be enrolled.
  • Known history of acute or chronic pancreatitis ≤ 6 months prior to reregistration.
  • Known positive serology for HIV (human immunodeficiency virus), active hepatitis B, and/or active hepatitis C infection.
  • Patients who have neuromuscular disorders that are associated with elevated CPK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy).
  • History of chronic inflammatory bowel disease or Crohn’s disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ≤ 12 months prior to Reregistration.
  • Impaired GI function or disease that may significantly alter the absorption of binimetinib or palbociclib (e.g., ulcerative disease, uncontrolled vomiting, malabsorption syndrome, small bowel resection with decreased intestinal absorption) in the opinion of the investigator.
  • History of retinal vein occlusion (RVO) or current risk factors to RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity, or hypercoagulability syndromes).
  • Leptomeningeal disease.
  • Known hypersensitivity to the components of study drugs or its analogs.
  • Known medical, psychiatric, substance abuse, or cognitive disorder that may compromise the patient’s ability to understand the patient information, give informed consent, comply with the study protocol, or complete the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements in the opinion of the investigator.
  • Patients who have undergone major surgery ≤ 21 days prior to Reregistration or who have not recovered from side effects of such procedures.
  • Any other co-morbid, systemic illnesses or other severe concurrent disease which, in the judgement of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Previous or concurrent malignancy ≤ 3 years prior to Re-registration with the following exceptions:
    • adequately treated basal cell or squamous cell carcinoma of the skin;
    • superficial bladder cancer;
    • prostate intraepithelial neoplasm;
    • in situ carcinoma of the cervix;
    • other solid tumors treated curatively without evidence of recurrence for ≥3 years prior to Re-registration.
    • Note: If there is a history or prior malignancy, must not be receiving other specific anti-cancer treatment such as anti-estrogen, antiandrogen, or other tyrosine kinase inhibitor.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Tanios Bekaii-Saab, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Tanios Bekaii-Saab, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Tanios Bekaii-Saab, M.D.

Contact us for the latest status

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions